🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,254 results for “First” Clear

  1. nab-paclitaxel combined with carboplatin

    First Tracks Biotherapeutics

    Epithelial Ovarian Carcinoma Stage III

    phase 3 small molecule active

    1 trial

  2. paclitaxel/anthracycline

    First Tracks Biotherapeutics

    Primary Breast Cancer

    phase 3 small molecule active

    1 trial

  3. patients undergo cVATS segmentectomy

    First Tracks Biotherapeutics

    Non-small Cell Lung Cancer Stage I

    phase 3 other active

    1 trial

  4. probiotics, antibiotics or antidepressants

    First Tracks Biotherapeutics

    Irritable Bowel Syndrome

    phase 3 small molecule active

    1 trial

  5. recombinant human erythropoietin

    First Tracks Biotherapeutics

    Lymphoma

    phase 3 small molecule active

    1 trial

  6. recombinant human thrombopoietin

    First Tracks Biotherapeutics

    Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  7. rhTPO

    First Tracks Biotherapeutics

    Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  8. the Shouhui Tongbian Capsule

    First Tracks Biotherapeutics

    OIC

    phase 3 small molecule active

    1 trial

  9. ticagrelor

    First Tracks Biotherapeutics

    Coronary Artery Disease

    phase 3 small molecule active

    1 trial

  10. venetoclax

    First Tracks Biotherapeutics

    Acute Promyelocytic Leukemia

    phase 3 small molecule active

    1 trial

  11. "Endostar"

    First Tracks Biotherapeutics

    Esophageal

    phase 2 small molecule terminated

    1 trial

  12. 0.9% sodium chloride

    First Tracks Biotherapeutics

    Kidney Disease, Chronic

    phase 2 small molecule active

    1 trial

  13. 177Lu-DOTA-EB-FAPI radionuclide therapy

    First Tracks Biotherapeutics

    Refractory Solid Tumor

    phase 2 small molecule completed

    1 trial

  14. 18F-92

    First Tracks Biotherapeutics

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  15. 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy

    First Tracks Biotherapeutics

    Cervical Cancer Stage IVA

    phase 2 other active

    1 trial

  16. 225Ac-LNC1011

    First Tracks Biotherapeutics

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  17. 3D hypoxia-preconditioned UC-MSC group

    First Tracks Biotherapeutics

    Severe Aplastic Anemia (SAA)

    phase 2 small molecule active

    1 trial

  18. 68Ga-DOTATATE and 68Ga-FAPI

    First Tracks Biotherapeutics

    Tumor Positron-Emission Tomography

    phase 2 small molecule completed

    1 trial

  19. 68Ga-FAP-CHX

    First Tracks Biotherapeutics

    Tumor

    phase 2 small molecule active

    1 trial

  20. 68Ga-G21

    First Tracks Biotherapeutics

    Prostate Cancer (Adenocarcinoma)

    phase 2 small molecule active

    1 trial

  21. 68Ga-NY104 PET/CT

    First Tracks Biotherapeutics

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  22. A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of GSK5458514 PSMA targeting T cell engager alone or in combination with other anti-cancer agents in adult participants with metastatic castration-resistant prostate cancer (mCRPC)

    GlaxoSmithKline Biologicals S.A.

    Neoplasms, Prostate

    phase 2 other active

    1 trial

  23. A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer

    Bristol-Myers Squibb / Pfizer EEIG

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  24. A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line metastatic urothelial carcinoma

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources